The Financial Supervisory Authority of Norway has on 16 June 2025 approved the
base prospectus with appendices prepared by Aker BioMarine ASA in connection
with the listing of the company's most recent bond issue on the Oslo Stock
Exchange: 
ISIN NO0013326025 - FRN Senior Secured Bond Issue 2024/2027

The prospectus with appendices and Final Terms is available on the company's
website: https://www.akerbiomarine.com/investor 

Lysaker, 16 June 2025
Aker BioMarine ASA

For further information, please contact 
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820 
Email:  Christopher.vinter@akerbiomarine.com  

This information is subject to the disclosure requirements pursuant to MAR
Article 19 and Section 5-12 of the Norwegian Securities Trading Act. 

About Aker BioMarine: 
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.